What side effects are associated with this type of intervention?

Minimally invasive surgeries for lung cancer, such as VATS and RATS lobectomy, typically result in fewer complications compared to open surgeries, with common side effects including pain, infection, and bleeding. Radiotherapy can cause fatigue, skin irritation, and pneumonitis, whereas chemotherapy often leads to nausea, vomiting, hair loss, and an increased risk of infection.

What prior FDA approvals exist?

The FDA has approved various treatments for lung cancer, including targeted therapies, immunotherapies, and surgical techniques. For minimally invasive surgical options, Video-Assisted Thoracoscopic Surgery (VATS) and Robotic-Assisted Thoracic Surgery (RATS) are notable. These techniques are used for early-stage lung cancer and involve smaller incisions, leading to quicker recovery times and fewer complications compared to traditional open surgery. While specific FDA approvals for RATS lobectomy are not detailed, the general approval of robotic-assisted surgical systems for thoracic procedures highlights the advancement in minimally invasive surgical options for lung cancer treatment.

What other types of research exist?

Promising alternatives to RATS lobectomy for lung cancer patients include Video-Assisted Thoracoscopic Surgery (VATS) and advancements in Stereotactic Radiosurgery (SRS). VATS is a well-established minimally invasive technique that offers shorter recovery times and fewer complications compared to open surgery. SRS, particularly for patients with limited brain metastases, provides a non-invasive option with high local control rates and the potential to avoid the side effects of whole-brain radiation therapy.

← Back to Search

Procedure

Robotic Lobectomy for Lung Cancer (OTC-RATS Trial)

N/A

Waitlist Available

Led By Moishe Liberman, MD

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new way to perform lung surgery using a robot through small cuts below the ribs. It targets patients with early-stage lung cancer who are already scheduled for minimally invasive surgery. The robot helps the surgeon make precise movements, which could reduce pain and speed up recovery. Robotic surgery has been increasingly used in thoracic procedures, offering benefits such as lower blood loss and improved lymph node removal.

Who is the study for?

This trial is for adults with early-stage lung cancer (stage I) who are already scheduled to have a lobectomy, which is surgery to remove a part of the lung, using minimally invasive techniques at CHUM. Pregnant individuals or those unable to consent are not eligible.

What is being tested?

The study is testing the feasibility and safety of performing robotic-assisted thoracic surgery (RATS) lobectomies outside the traditional setting ('Outside the Cage') in patients with stage I lung cancer.

What are the potential side effects?

While specific side effects aren't listed, typical risks may include complications from surgery such as pain, infection, bleeding, and issues related to anesthesia.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

30-day mortality

Conversion rate

Secondary study objectives

Analgesic complementation requirement

Estimated blood loss

Evaluate Chronic Pain

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Out of the Cage Robotic LobectomyExperimental Treatment1 Intervention

Consented patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, except for the incisions, that will consist in 1 to 4 subcostal ports, based on the patient and case characteristics.

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for lung cancer include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Surgery, such as RATS Lobectomy, involves the physical removal of the tumor and is crucial for early-stage lung cancer as it can potentially cure the disease. Radiation therapy uses high-energy rays to kill cancer cells, often used when surgery isn't an option. Chemotherapy involves drugs that kill rapidly dividing cells, including cancer cells, and is used for more advanced stages. Targeted therapy focuses on specific genetic mutations in cancer cells, offering a more personalized treatment with potentially fewer side effects. Immunotherapy boosts the body's immune system to fight cancer. These treatments are vital as they offer multiple approaches to manage and potentially cure lung cancer, improving survival rates and quality of life for patients.

Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?The management of non-small-cell lung cancer: a case history.